Clinical Trial Update: A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 trial of lampalizumab for geographic atrophy due to age-related macular degeneration was terminated with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• lampalizumab (lampalizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Geographic Atrophy | Phase 3 | Status: TERMINATED | Results posted: 2019-04-23